Investor Relations

With the CE mark expansion for Ambu^® aScope™ 5 Cysto HD, urologists will now be able to use the medical technology as a single-use flexible cysto-nephroscopy solution, reflecting Ambu’s commitment to addressing a growing range of urology needs for patients and healthcare professionals.

Today, Ambu announces expansion of the European regulatory clearance (CE mark) for its Ambu^® aScope™ 5 Cysto HD solution. This additional clearance enables Ambu’s existing HD technology to function as a single-use flexible cysto-nephroscopy solution, addressing a new niche procedure within urology.

In the operating room, cysto-nephroscopes are used to perform percutaneous nephrolithotomy (PCNL) procedures – a minimally invasive procedure designed to remove large and complex kidney stones. This technique involves creating a small passageway to the kidney through a small incision in the patient’s back.

Globally, ~300,000 PCNL procedures are performed every year. In spite of the narrow market, the extended CE mark clearance is a reinforcement of Ambu’s commitment to advancing urological care by meeting a wide range of procedural needs through an extensive and versatile urology portfolio.

Integrated with the company’s digital endoscopy systems, Ambu^® aView™ 2 Advance and Ambu^® aBox™ 2, Ambu’s cysto-nephroscope and newly launched ureteroscope are designed to complement one another. The endoscopy systems enable simultaneous connection, providing urologists with a dual view of the Ambu^® aScope™ 5 Uretero and Ambu^® aScope™ 5 Cysto HD during combined PCNL and ureteroscopy procedures.

Ambu will now engage in a controlled market release, kick-starting the initial evaluation phase to assess the solution’s performance in PCNL procedures at key European hospitals.

"This expanded European clearance reflects our dedication to addressing a growing range of customer needs in urology. Although the market potential for procedures requiring cysto-nephroscopes is relatively modest, this expansion showcases our ongoing efforts to enhance our urology offering and provide the best possible care and solutions to urologists and their patients."

BRITT MEELBY JENSEN
Chief Executive Officer, Ambu 

Read the full press release here

Ambu A/S (Ambu) launches a new share based Long-Term Incentive Plan (LTIP) for the Executive Management and selected key employees for 2024/25, in accordance with Ambu’s Remuneration Policy. The LTIP is designed to align the interests of employees and shareholders, ensuring that employees are retained and rewarded for their dedicated efforts in achieving the company’s strategic and long-term objectives. The LTIP for 2024/25 has been approved by the Board of Directors. 

The LTIP implies the grant of a total of 175,477 performance share units (PSUs) for 2024/25. These grants will be issued with retroactive effect from 1 January 2025. Of these, 49,246 PSUs are allocated to the Executive Management, while 126,231 of the PSUs are allocated to other key employees.  

The LTIP is tied to the financial year 2024/25. The performance period covers the full financial year, and the final allocation of PSUs depends on the achievement of key performance indicators (KPIs) relating to organic revenue growth and EBIT before special items for the fiscal year 2024/25. Each KPI is defined by a target and a threshold. If the performance is below the threshold, no PSUs will be granted. The allocation can range from 0-200% of the initial grant. The value of the PSUs will, at the time of vesting, be capped at four times the annual base salary of the individual participant, measured at the time of the grant.  

The PSUs are granted free of charge and subject to achievement of the KPIs mentioned above. Upon vesting on 1 January 2028, each PSU will convert into one Class B share in Ambu A/S, subject to the terms of the LTIP.  

The allocation of shares is based on the average price for Ambu A/S’ Class B shares listed on Nasdaq OMX Copenhagen on the day of the annual general meeting and the subsequent four (4) trading days (4-10 December 2024).

Download the company announcement here.

In the first quarter of the 2024/25 financial year, Ambu delivered 19.5% organic revenue growth and a 16.1% EBIT margin before special items, driven by continued solid momentum in Endoscopy Solutions, which grew by 20.6%, and strong performance in Anaesthesia & Patient Monitoring, which grew by 17.8%, mainly related to price increases and solid volume growth.

On January 9, 2025, Ambu adjusted its full-year financial guidance by upgrading the expectations for organic revenue growth to 11-14% (previously 10-13%) and for EBIT margin before special items to 13-15% (previously 12-14%). The upgrade was mainly related to strong performance in Anaesthesia & Patient Monitoring, supported by continued solid growth in Endoscopy Solutions.

“I am pleased with the strong start we have had to the financial year, delivering growth and profitability above expectations and achieving notable milestones. We continued our strong momentum in Endoscopy Solutions, with robust pulmonology growth, and delivered significant performance improvement in Anaesthesia & Patient Monitoring.

In 2025, we will launch our new video laryngoscopy solution, Ambu® SureSightTM  Connect, expanding our pulmonology portfolio with a unique offering. With bioplastics now in all our endoscope handles, I’m excited for another year of supporting customers with innovative solutions that improve patient care, together with my Ambu colleagues worldwide.“

BRITT MEELBY JENSEN
Chief Executive Officer

HIGHLIGHTS FOR THE QUARTER

Last year’s comparative figures are presented in brackets.

Financial highlights

• Revenue increased organically by 19.5% (14.2%) to DKK 1,510m (DKK 1,254m), with reported growth of 20.4% (10.9%).
• Endoscopy Solutions revenue increased organically by 20.6% (25.1%). Pulmonology posted 17.7% (18.1%) organic growth, and urology, ENT and GI posted 23.9% (34.2%) organic growth, combined.
• Anaesthesia & Patient Monitoring increased organically by 17.8% (1.2%), positively impacted by price increases and solid volume growth.
• EBIT before special items (b.s.i.) was DKK 243m (DKK 126m), with an EBIT margin b.s.i. of 16.1% (10.0%). The increase was primarily driven by organic revenue growth.  
• Free cash flow before acquisitions totalled DKK 69m (DKK 135m). This was positively impacted by increased profitability and trade payables, although offset by increased inventory levels, due to preparations pertaining to new product launches, higher trade receivables, as well as higher investments.
• At Ambu’s annual general meeting 2024, it was decided to pay out dividends worth DKK 102m (DKK 0.38 per share).
• The adjusted 2024/25 financial guidance, stated on 9 January 2025, is maintained:
  • Organic revenue growth: 11-14%
  • Reported EBIT margin before special items: 13-15%
  • Free cash flow: DKK +500m

Business highlights

• Strengthened pulmonology offering with the registration of Ambu® SureSight™ Connect, Ambu’s new video laryngoscopy solution.
• Commercial launch of Ambu’s ureteroscopy solution, Ambu® aScope™ 5 Uretero.
• Bioplastic materials implemented in the handle of all Ambu’s marketed endoscopes, marking an important step in transforming the industry towards sustainable endoscopy

DOWNLOAD
Download and read the full Q1 2024/25 earnings release here

Q1 2024/25 CONFERENCE CALL
A conference call is broadcast live today, Thursday 30 January 2025, at 11:00 (CET), via ambu.com/webcastQ12025. To ask questions during the Q&A session, please register prior to the call via ambu.com/conferencecallQ12025register. Upon registration, you will receive an e-mail with information to access the call.
The presentation can be downloaded at Ambu.com/presentations.